Science Advances-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给williamhill asia 的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=205, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2150108, encodeId=dd57215010844, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：亲身经历，杂志社效率极低，有其他选择的就不要投这个，初审editor decision要一个月，外审一年的挺多的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84f12054797, createdName=LL之, createdTime=Thu Jul 27 14:19:28 CST 2023, time=2023-07-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147123, encodeId=1993214e12379, content=偏重的研究方向：纳米科学 经验分享：准备投了，希望今年可以中一篇，需要一点好运气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220218/30ddc186635d417c9b0ef75136af0994/13086d24185340e2aaa2dcbe5fc9b130.jpg, createdBy=d6df2504618, createdName=实验室包工头, createdTime=Sun Jul 09 14:22:50 CST 2023, time=2023-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125857, encodeId=992a212585e5b, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：等待煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9578600405, createdName=ms4000001399579030, createdTime=Fri Apr 14 10:26:25 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=861406, encodeId=fb7f86140618, content=审稿速度:1.0 经验分享：大佬们的游戏而已，注定没法和pnas和子刊比 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=557, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Thu Jun 04 09:47:58 CST 2020, time=2020-06-04, status=1, ipAttribution=)]

2022-09-22 a201061519

偏重的研究方向：肿瘤
经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！

263 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给williamhill asia 的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=205, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2150108, encodeId=dd57215010844, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：亲身经历，杂志社效率极低，有其他选择的就不要投这个，初审editor decision要一个月，外审一年的挺多的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84f12054797, createdName=LL之, createdTime=Thu Jul 27 14:19:28 CST 2023, time=2023-07-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147123, encodeId=1993214e12379, content=偏重的研究方向：纳米科学 经验分享：准备投了，希望今年可以中一篇，需要一点好运气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220218/30ddc186635d417c9b0ef75136af0994/13086d24185340e2aaa2dcbe5fc9b130.jpg, createdBy=d6df2504618, createdName=实验室包工头, createdTime=Sun Jul 09 14:22:50 CST 2023, time=2023-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125857, encodeId=992a212585e5b, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：等待煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9578600405, createdName=ms4000001399579030, createdTime=Fri Apr 14 10:26:25 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=861406, encodeId=fb7f86140618, content=审稿速度:1.0 经验分享：大佬们的游戏而已，注定没法和pnas和子刊比 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=557, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Thu Jun 04 09:47:58 CST 2020, time=2020-06-04, status=1, ipAttribution=)]

2020-04-13 ms313574960747337

审稿速度:10.0
经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。

177 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给williamhill asia 的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=205, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2150108, encodeId=dd57215010844, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：亲身经历，杂志社效率极低，有其他选择的就不要投这个，初审editor decision要一个月，外审一年的挺多的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84f12054797, createdName=LL之, createdTime=Thu Jul 27 14:19:28 CST 2023, time=2023-07-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147123, encodeId=1993214e12379, content=偏重的研究方向：纳米科学 经验分享：准备投了，希望今年可以中一篇，需要一点好运气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220218/30ddc186635d417c9b0ef75136af0994/13086d24185340e2aaa2dcbe5fc9b130.jpg, createdBy=d6df2504618, createdName=实验室包工头, createdTime=Sun Jul 09 14:22:50 CST 2023, time=2023-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125857, encodeId=992a212585e5b, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：等待煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9578600405, createdName=ms4000001399579030, createdTime=Fri Apr 14 10:26:25 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=861406, encodeId=fb7f86140618, content=审稿速度:1.0 经验分享：大佬们的游戏而已，注定没法和pnas和子刊比 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=557, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Thu Jun 04 09:47:58 CST 2020, time=2020-06-04, status=1, ipAttribution=)]

2020-06-13 ms3036779279854874

审稿速度:4.0
经验分享：20200127 投稿
20200327 第一轮修改，三个审稿人（两个小修，一个大修）
20200505 第一轮修改，三个审稿人（两个同意接收，一个小修）
20200528 accept-technical hold
20200602 付版面费 4500 usd
20200612 accepted
希望对投稿的人有所帮助！！！

637 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给williamhill asia 的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=205, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2150108, encodeId=dd57215010844, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：亲身经历，杂志社效率极低，有其他选择的就不要投这个，初审editor decision要一个月，外审一年的挺多的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84f12054797, createdName=LL之, createdTime=Thu Jul 27 14:19:28 CST 2023, time=2023-07-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147123, encodeId=1993214e12379, content=偏重的研究方向：纳米科学 经验分享：准备投了，希望今年可以中一篇，需要一点好运气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220218/30ddc186635d417c9b0ef75136af0994/13086d24185340e2aaa2dcbe5fc9b130.jpg, createdBy=d6df2504618, createdName=实验室包工头, createdTime=Sun Jul 09 14:22:50 CST 2023, time=2023-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125857, encodeId=992a212585e5b, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：等待煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9578600405, createdName=ms4000001399579030, createdTime=Fri Apr 14 10:26:25 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=861406, encodeId=fb7f86140618, content=审稿速度:1.0 经验分享：大佬们的游戏而已，注定没法和pnas和子刊比 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=557, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Thu Jun 04 09:47:58 CST 2020, time=2020-06-04, status=1, ipAttribution=)]

2022-08-06 马疾香幽

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：免疫;肿瘤;生物信息
经验分享：第14天被拒。整体速度感觉偏慢吧。

244 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给williamhill asia 的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=205, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2150108, encodeId=dd57215010844, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：亲身经历，杂志社效率极低，有其他选择的就不要投这个，初审editor decision要一个月，外审一年的挺多的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84f12054797, createdName=LL之, createdTime=Thu Jul 27 14:19:28 CST 2023, time=2023-07-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147123, encodeId=1993214e12379, content=偏重的研究方向：纳米科学 经验分享：准备投了，希望今年可以中一篇，需要一点好运气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220218/30ddc186635d417c9b0ef75136af0994/13086d24185340e2aaa2dcbe5fc9b130.jpg, createdBy=d6df2504618, createdName=实验室包工头, createdTime=Sun Jul 09 14:22:50 CST 2023, time=2023-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125857, encodeId=992a212585e5b, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：等待煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9578600405, createdName=ms4000001399579030, createdTime=Fri Apr 14 10:26:25 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=861406, encodeId=fb7f86140618, content=审稿速度:1.0 经验分享：大佬们的游戏而已，注定没法和pnas和子刊比 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=557, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Thu Jun 04 09:47:58 CST 2020, time=2020-06-04, status=1, ipAttribution=)]

2023-08-02 丹丹同学来自江苏省

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：医学;肿瘤
经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛

128 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给williamhill asia 的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=205, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2150108, encodeId=dd57215010844, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：亲身经历，杂志社效率极低，有其他选择的就不要投这个，初审editor decision要一个月，外审一年的挺多的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84f12054797, createdName=LL之, createdTime=Thu Jul 27 14:19:28 CST 2023, time=2023-07-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147123, encodeId=1993214e12379, content=偏重的研究方向：纳米科学 经验分享：准备投了，希望今年可以中一篇，需要一点好运气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220218/30ddc186635d417c9b0ef75136af0994/13086d24185340e2aaa2dcbe5fc9b130.jpg, createdBy=d6df2504618, createdName=实验室包工头, createdTime=Sun Jul 09 14:22:50 CST 2023, time=2023-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125857, encodeId=992a212585e5b, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：等待煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9578600405, createdName=ms4000001399579030, createdTime=Fri Apr 14 10:26:25 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=861406, encodeId=fb7f86140618, content=审稿速度:1.0 经验分享：大佬们的游戏而已，注定没法和pnas和子刊比 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=557, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Thu Jun 04 09:47:58 CST 2020, time=2020-06-04, status=1, ipAttribution=)]

2023-02-19 Candy啦来自四川省

审稿速度:6.0 | 投稿命中率:5.0
偏重的研究方向：基础实验
经验分享：10.15投稿
中间一周换一次日期
11.25送审
11.28更新to review
2022.12.23更新to review
2023.1.8更新to review
2023.1.12更新to review
2023.1.15更新to review
2023.1.29更新to review
2023.1.31更新to review
2023.2.3更新to review
2023.2.4更新to review
2023.2.8更新to review
2023.2.18 reject
这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给williamhill asia 的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！

205 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给williamhill asia 的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=205, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2150108, encodeId=dd57215010844, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：亲身经历，杂志社效率极低，有其他选择的就不要投这个，初审editor decision要一个月，外审一年的挺多的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84f12054797, createdName=LL之, createdTime=Thu Jul 27 14:19:28 CST 2023, time=2023-07-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147123, encodeId=1993214e12379, content=偏重的研究方向：纳米科学 经验分享：准备投了，希望今年可以中一篇，需要一点好运气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220218/30ddc186635d417c9b0ef75136af0994/13086d24185340e2aaa2dcbe5fc9b130.jpg, createdBy=d6df2504618, createdName=实验室包工头, createdTime=Sun Jul 09 14:22:50 CST 2023, time=2023-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125857, encodeId=992a212585e5b, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：等待煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9578600405, createdName=ms4000001399579030, createdTime=Fri Apr 14 10:26:25 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=861406, encodeId=fb7f86140618, content=审稿速度:1.0 经验分享：大佬们的游戏而已，注定没法和pnas和子刊比 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=557, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Thu Jun 04 09:47:58 CST 2020, time=2020-06-04, status=1, ipAttribution=)]

2023-07-27 LL之来自上海

审稿速度:24.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：亲身经历，杂志社效率极低，有其他选择的就不要投这个，初审editor decision要一个月，外审一年的挺多的

138 0

[GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给williamhill asia 的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=205, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2150108, encodeId=dd57215010844, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：亲身经历，杂志社效率极低，有其他选择的就不要投这个，初审editor decision要一个月，外审一年的挺多的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84f12054797, createdName=LL之, createdTime=Thu Jul 27 14:19:28 CST 2023, time=2023-07-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147123, encodeId=1993214e12379, content=偏重的研究方向：纳米科学 经验分享：准备投了，希望今年可以中一篇，需要一点好运气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220218/30ddc186635d417c9b0ef75136af0994/13086d24185340e2aaa2dcbe5fc9b130.jpg, createdBy=d6df2504618, createdName=实验室包工头, createdTime=Sun Jul 09 14:22:50 CST 2023, time=2023-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125857, encodeId=992a212585e5b, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：等待煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9578600405, createdName=ms4000001399579030, createdTime=Fri Apr 14 10:26:25 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=861406, encodeId=fb7f86140618, content=审稿速度:1.0 经验分享：大佬们的游戏而已，注定没法和pnas和子刊比 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=557, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Thu Jun 04 09:47:58 CST 2020, time=2020-06-04, status=1, ipAttribution=)]

2023-07-09 实验室包工头

偏重的研究方向：纳米科学
经验分享：准备投了，希望今年可以中一篇，需要一点好运气

124 0

[GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给williamhill asia 的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=205, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2150108, encodeId=dd57215010844, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：亲身经历，杂志社效率极低，有其他选择的就不要投这个，初审editor decision要一个月，外审一年的挺多的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84f12054797, createdName=LL之, createdTime=Thu Jul 27 14:19:28 CST 2023, time=2023-07-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147123, encodeId=1993214e12379, content=偏重的研究方向：纳米科学 经验分享：准备投了，希望今年可以中一篇，需要一点好运气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220218/30ddc186635d417c9b0ef75136af0994/13086d24185340e2aaa2dcbe5fc9b130.jpg, createdBy=d6df2504618, createdName=实验室包工头, createdTime=Sun Jul 09 14:22:50 CST 2023, time=2023-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125857, encodeId=992a212585e5b, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：等待煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9578600405, createdName=ms4000001399579030, createdTime=Fri Apr 14 10:26:25 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=861406, encodeId=fb7f86140618, content=审稿速度:1.0 经验分享：大佬们的游戏而已，注定没法和pnas和子刊比 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=557, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Thu Jun 04 09:47:58 CST 2020, time=2020-06-04, status=1, ipAttribution=)]

2023-04-14 ms4000001399579030 来自山东省

审稿速度:12.0 | 投稿命中率:25.0
经验分享：等待煎熬中

168 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=263, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给williamhill asia 的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=205, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2150108, encodeId=dd57215010844, content=审稿速度:24.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：亲身经历，杂志社效率极低，有其他选择的就不要投这个，初审editor decision要一个月，外审一年的挺多的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84f12054797, createdName=LL之, createdTime=Thu Jul 27 14:19:28 CST 2023, time=2023-07-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147123, encodeId=1993214e12379, content=偏重的研究方向：纳米科学 经验分享：准备投了，希望今年可以中一篇，需要一点好运气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220218/30ddc186635d417c9b0ef75136af0994/13086d24185340e2aaa2dcbe5fc9b130.jpg, createdBy=d6df2504618, createdName=实验室包工头, createdTime=Sun Jul 09 14:22:50 CST 2023, time=2023-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125857, encodeId=992a212585e5b, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：等待煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9578600405, createdName=ms4000001399579030, createdTime=Fri Apr 14 10:26:25 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=861406, encodeId=fb7f86140618, content=审稿速度:1.0 经验分享：大佬们的游戏而已，注定没法和pnas和子刊比 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=557, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e295414102, createdName=ms4512939187244456, createdTime=Thu Jun 04 09:47:58 CST 2020, time=2020-06-04, status=1, ipAttribution=)]

2020-06-04 ms4512939187244456

审稿速度:1.0
经验分享：大佬们的游戏而已，注定没法和pnas和子刊比

557 6

展开6条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务